Solasia Pharma KK (DE:9SO)
FRANKFURT:9SO
9SO Stock Chart & Stats
€0.14
<€0.01(2.88%)
At close: 4:00 PM EST
€0.14
<€0.01(2.88%)
Day’s Range― - ―
52-Week Range€0.13 - €0.24
Previous CloseN/A
Volume0.00
Average Volume (3M)35.00
Market Cap
€50.46M
Enterprise Value€8.05B
Total Cash (Recent Filing)€1.39B
Total Debt (Recent Filing)€159.00M
Price to Earnings (P/E)―
Beta0.22
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding273,414,370
10 Day Avg. Volume107
30 Day Avg. Volume35
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)3.93
Price to Sales (P/S)16.06
P/FCF Ratio-8.13
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€10.59M
Bulls Say, Bears Say
Bulls Say
Revenue Recovery & GrowthRevenue rebound in 2025 signals recovering product demand and improving commercial traction after several choppy years. Sustained top-line growth enhances operating leverage potential, reducing the scale of losses needed to approach breakeven and supporting longer-term investment plans.
Low Leverage Balance SheetVery low leverage (debt-to-equity ~0.09) provides material financial flexibility for a loss-making specialty pharma. It extends runway for R&D and commercialization, lowers near-term solvency risk, and gives management time to execute strategic initiatives without immediate refinancing pressure.
Improving Cash Burn TrendMaterial improvement in free cash flow year-over-year indicates operational discipline or better revenue mix. A demonstrable reduction in cash burn, if sustained, reduces external funding needs, preserves equity, and is a necessary precursor to achieving durable positive cash generation.
Bears Say
Persistent Operating & Net LossesLarge recurring operating and net losses—with a deeply negative 2025 net margin—show the cost base remains far above current revenue. Continued losses will erode equity over time, necessitate recurring financing or dilution, and make achieving sustainable profitability more difficult.
Negative Free Cash Flow Every YearConsistent negative operating and free cash flow means the business is reliant on external financing or balance-sheet resources to operate. Chronic negative FCF increases funding risk, raises likelihood of dilution or debt, and constrains the firm's ability to invest in growth without clear cash-flow improvement.
Declining Gross MarginSharp gross margin compression reduces the cash conversion efficiency of revenue and lengthens the revenue runway required to reach profitability. Margin deterioration may reflect cost pressures, pricing mix changes, or lower-priced product mix, making the path to sustainable profits harder.
Solasia Pharma KK News
9SO FAQ
What was Solasia Pharma KK’s price range in the past 12 months?
Solasia Pharma KK lowest stock price was €0.13 and its highest was €0.24 in the past 12 months.
What is Solasia Pharma KK’s market cap?
Solasia Pharma KK’s market cap is €50.46M.
When is Solasia Pharma KK’s upcoming earnings report date?
Solasia Pharma KK’s upcoming earnings report date is May 20, 2026 which is in 45 days.
How were Solasia Pharma KK’s earnings last quarter?
Solasia Pharma KK released its earnings results on Feb 13, 2026. The company reported -€0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.003.
Is Solasia Pharma KK overvalued?
According to Wall Street analysts Solasia Pharma KK’s price is currently Overvalued.
Does Solasia Pharma KK pay dividends?
Solasia Pharma KK does not currently pay dividends.
What is Solasia Pharma KK’s EPS estimate?
Solasia Pharma KK’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Solasia Pharma KK have?
Solasia Pharma KK has 273,414,370 shares outstanding.
What happened to Solasia Pharma KK’s price movement after its last earnings report?
Solasia Pharma KK reported an EPS of -€0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.974%.
Which hedge fund is a major shareholder of Solasia Pharma KK?
Currently, no hedge funds are holding shares in DE:9SO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Solasia Pharma KK
Solasia Pharma K.K. develops and commercializes drugs in the field of oncology in Japan and other Asian countries. The company offers SP-03 (episil oral liquid) for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; and SP-01 (Sancuso), a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02 (Darinaparsin), a mitochondrial-targeted agent that has completed phase III clinical study to treat various hematologic and solid cancers; and SP-04 a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. In addition, the company is developing SP-05 (Arfolitixorin) that is in phase III clinical study for the enhancement of antitumor efficacy of fluorouracil, including the treatment for pancreatic cancer, breast cancer, stomach cancer, and head and neck cancers. Solasia Pharma K.K. was founded in 2006 and is based in Tokyo, Japan.
Technical Analysis
Nippon Chemiphar Co., Ltd.
―
Taiko Pharmaceutical Co., Ltd.
―
Symbio Pharmaceuticals Limited
―
Modalis Therapeutics Corporation
―
Cyfuse Biomedical K.K.
―
Options Prices
Currently, No data available
---